Bone-seeking radionuclides for therapy

Area of Science:

• Nuclear medicine
• Oncology
• Radiopharmacology

Background:

• Multisite metastatic bone pain is a significant clinical challenge.
• Systemic therapy with bone-seeking radiopharmaceuticals offers a targeted approach for pain palliation.

Purpose of the Study:

• To review evidence for beta, electron, and alpha-particle-emitting radiopharmaceuticals in treating bone metastases.
• To discuss patient selection, radionuclide tailoring, and toxicity management.
• To explore the role of targeted therapy in multimodality cancer treatment.

Main Methods:

• Review of existing literature on radiopharmaceutical therapy for bone metastases.
• Correlation of clinical symptoms with bone scintigraphy findings for patient selection.
• Analysis of radionuclide properties (half-life, dose rate) influencing treatment response.
• Evaluation of myelosuppression as a primary toxicity, dependent on activity and bone marrow reserve.

Main Results:

• Radiopharmaceuticals provide advantages for multisite metastatic pain.
• Patient selection is key, guided by scintigraphy.
• Tailoring radionuclide choice based on physical characteristics optimizes symptom relief duration.
• Temporary myelosuppression is the main toxicity, manageable by dose adjustment.
• Optimal responses are seen in patients with moderate skeletal tumor burden.

Conclusions:

• Targeted radiopharmaceutical therapy should be considered early in bone metastasis management.
• Dosimetric models are needed for personalized prescribing to balance efficacy and toxicity.
• Multimodality approaches combining radiopharmaceuticals with other treatments may enhance outcomes beyond palliation, potentially improving survival.